Medical Care
Global mRNA Cancer Vaccines and Therapeutics Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
- Jun 23, 25
- ID: 322785
- Pages: 117
- Figures: 130
- Views: 64
In 2024, the global market size of mRNA Cancer Vaccines and Therapeutics was estimated to be worth US$ 198 million and is forecast to reach approximately US$ 659 million by 2031 with a CAGR of 19.0% during the forecast period 2025-2031.
mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
North America is the largest mRNA Cancer Vaccines and Therapeutics market with about 69% market share. Europe is follower, accounting for about 28% market share.
The key players are Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology etc. Top 3 companies occupied about 82% market share.
Report Scope
This report aims to provide a comprehensive presentation of the global market for mRNA Cancer Vaccines and Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding mRNA Cancer Vaccines and Therapeutics.
The mRNA Cancer Vaccines and Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global mRNA Cancer Vaccines and Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the mRNA Cancer Vaccines and Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
Moderna Therapeutics
CureVac
Translate Bio
BioNTech
Sangamo Therapeutics
Argos Therapeutics
In-Cell-Art
eTheRNA
Ethris
Tiba Biotechnology
Segment by Type
Adeno Carcinomas
Mucinous Carcinomas
Adenosquamous Carcinomas
Segment by Application
Infectious Disease
Cancer
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of mRNA Cancer Vaccines and Therapeutics in global and regional level.
Chapter 3: Detailed analysis of mRNA Cancer Vaccines and Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, mRNA Cancer Vaccines and Therapeutics revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
mRNA is a rather versatile technology and offers a number of advantages. mRNA lacks genomic integration and its use results in transient expression of the encoded protein. This favorable safety profile makes mRNA especially attractive for vaccines and gene editing. mRNA is well defined chemically which ensures reproducible manufacturing at high yield, purity and activity. Improvements of lipid nanoparticle formulations as a vehicle for in vivo systemic delivery of mRNA has greatly favored the development of in vivo transfection strategies.
North America is the largest mRNA Cancer Vaccines and Therapeutics market with about 69% market share. Europe is follower, accounting for about 28% market share.
The key players are Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology etc. Top 3 companies occupied about 82% market share.
Report Scope
This report aims to provide a comprehensive presentation of the global market for mRNA Cancer Vaccines and Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding mRNA Cancer Vaccines and Therapeutics.
The mRNA Cancer Vaccines and Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global mRNA Cancer Vaccines and Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the mRNA Cancer Vaccines and Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
Moderna Therapeutics
CureVac
Translate Bio
BioNTech
Sangamo Therapeutics
Argos Therapeutics
In-Cell-Art
eTheRNA
Ethris
Tiba Biotechnology
Segment by Type
Adeno Carcinomas
Mucinous Carcinomas
Adenosquamous Carcinomas
Segment by Application
Infectious Disease
Cancer
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of mRNA Cancer Vaccines and Therapeutics in global and regional level.
Chapter 3: Detailed analysis of mRNA Cancer Vaccines and Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, mRNA Cancer Vaccines and Therapeutics revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion
1 Study Coverage
1.1 mRNA Cancer Vaccines and Therapeutics Product Introduction
1.2 Market by Type
1.2.1 Global mRNA Cancer Vaccines and Therapeutics Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Adeno Carcinomas
1.2.3 Mucinous Carcinomas
1.2.4 Adenosquamous Carcinomas
1.3 Market by Application
1.3.1 Global mRNA Cancer Vaccines and Therapeutics Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Infectious Disease
1.3.3 Cancer
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global mRNA Cancer Vaccines and Therapeutics Market Size Estimates and Forecasts
2.2 mRNA Cancer Vaccines and Therapeutics Market Size by Region: 2024 Versus 2031
2.2.1 Global mRNA Cancer Vaccines and Therapeutics Revenue by Region: 2020-2025
2.2.2 Global mRNA Cancer Vaccines and Therapeutics Revenue Forecast by Region (2026-2031)
2.2.3 Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global mRNA Cancer Vaccines and Therapeutics Revenue by Type (2020-2031)
3.1.2 Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global mRNA Cancer Vaccines and Therapeutics Revenue by Application (2020-2031)
3.2.2 Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Adeno Carcinomas of mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application
3.3.2 Mucinous Carcinomas of mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application
3.3.3 Adenosquamous Carcinomas of mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application
4 Global mRNA Cancer Vaccines and Therapeutics by Company
4.1 Global mRNA Cancer Vaccines and Therapeutics Revenue by Company (2020-2025)
4.2 Global mRNA Cancer Vaccines and Therapeutics Revenue Share by Company (2020-2025)
4.3 Competitive Landscape
4.3.1 Key mRNA Cancer Vaccines and Therapeutics Companies around the World: Ranking by Revenue
4.3.2 Global mRNA Cancer Vaccines and Therapeutics Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.3.3 Global mRNA Cancer Vaccines and Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 Global mRNA Cancer Vaccines and Therapeutics Companies Headquarters & Product Type
4.4.1 Global mRNA Cancer Vaccines and Therapeutics Companies Headquarters
4.4.2 Date of International Companies Enter into mRNA Cancer Vaccines and Therapeutics Market
4.4.3 Global mRNA Cancer Vaccines and Therapeutics Companies Product & Service
4.4.4 Adeno Carcinomas Revenue Market Share of mRNA Cancer Vaccines and Therapeutics by Company
4.4.5 Mucinous Carcinomas Revenue Market Share of mRNA Cancer Vaccines and Therapeutics by Company
4.4.6 Adenosquamous Carcinomas Revenue Market Share of mRNA Cancer Vaccines and Therapeutics by Company
4.5 Global mRNA Cancer Vaccines and Therapeutics Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Moderna Therapeutics
5.1.1 Moderna Therapeutics Corporation Information
5.1.2 Moderna Therapeutics Description, Business Overview
5.1.3 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Products Offered
5.1.4 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2020-2025)
5.1.5 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue by Product in 2024
5.1.6 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue by Application in 2024
5.1.7 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue by Geographic Area in 2024
5.1.8 Moderna Therapeutics Recent Developments
5.2 CureVac
5.2.1 CureVac Corporation Information
5.2.2 CureVac Description, Business Overview
5.2.3 CureVac mRNA Cancer Vaccines and Therapeutics Products Offered
5.2.4 CureVac mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2020-2025)
5.2.5 CureVac mRNA Cancer Vaccines and Therapeutics Revenue by Product in 2024
5.2.6 CureVac mRNA Cancer Vaccines and Therapeutics Revenue by Application in 2024
5.2.7 CureVac mRNA Cancer Vaccines and Therapeutics Revenue by Geographic Area in 2024
5.2.8 CureVac Recent Developments
5.3 Translate Bio
5.3.1 Translate Bio Corporation Information
5.3.2 Translate Bio Description, Business Overview
5.3.3 Translate Bio mRNA Cancer Vaccines and Therapeutics Products Offered
5.3.4 Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2020-2025)
5.3.5 Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue by Product in 2024
5.3.6 Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue by Application in 2024
5.3.7 Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue by Geographic Area in 2024
5.3.8 Translate Bio Recent Developments
5.4 BioNTech
5.4.1 BioNTech Corporation Information
5.4.2 BioNTech Description, Business Overview
5.4.3 BioNTech mRNA Cancer Vaccines and Therapeutics Products Offered
5.4.4 BioNTech mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2020-2025)
5.4.5 BioNTech mRNA Cancer Vaccines and Therapeutics Revenue by Product in 2024
5.4.6 BioNTech mRNA Cancer Vaccines and Therapeutics Revenue by Application in 2024
5.4.7 BioNTech mRNA Cancer Vaccines and Therapeutics Revenue by Geographic Area in 2024
5.4.8 BioNTech Recent Developments
5.5 Sangamo Therapeutics
5.5.1 Sangamo Therapeutics Corporation Information
5.5.2 Sangamo Therapeutics Description, Business Overview
5.5.3 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Products Offered
5.5.4 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2020-2025)
5.5.5 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue by Product in 2024
5.5.6 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue by Application in 2024
5.5.7 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue by Geographic Area in 2024
5.5.8 Sangamo Therapeutics Recent Developments
5.6 Argos Therapeutics
5.6.1 Argos Therapeutics Corporation Information
5.6.2 Argos Therapeutics Description, Business Overview
5.6.3 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Products Offered
5.6.4 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2020-2025)
5.6.5 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue by Product in 2024
5.6.6 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue by Application in 2024
5.6.7 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue by Geographic Area in 2024
5.6.8 Argos Therapeutics Recent Developments
5.7 In-Cell-Art
5.7.1 In-Cell-Art Corporation Information
5.7.2 In-Cell-Art Description, Business Overview
5.7.3 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Products Offered
5.7.4 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2020-2025)
5.7.5 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue by Product in 2024
5.7.6 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue by Application in 2024
5.7.7 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue by Geographic Area in 2024
5.7.8 In-Cell-Art Recent Developments
5.8 eTheRNA
5.8.1 eTheRNA Corporation Information
5.8.2 eTheRNA Description, Business Overview
5.8.3 eTheRNA mRNA Cancer Vaccines and Therapeutics Products Offered
5.8.4 eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2020-2025)
5.8.5 eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue by Product in 2024
5.8.6 eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue by Application in 2024
5.8.7 eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue by Geographic Area in 2024
5.8.8 eTheRNA Recent Developments
5.9 Ethris
5.9.1 Ethris Corporation Information
5.9.2 Ethris Description, Business Overview
5.9.3 Ethris mRNA Cancer Vaccines and Therapeutics Products Offered
5.9.4 Ethris mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2020-2025)
5.9.5 Ethris mRNA Cancer Vaccines and Therapeutics Revenue by Product in 2024
5.9.6 Ethris mRNA Cancer Vaccines and Therapeutics Revenue by Application in 2024
5.9.7 Ethris mRNA Cancer Vaccines and Therapeutics Revenue by Geographic Area in 2024
5.9.8 Ethris Recent Developments
5.10 Tiba Biotechnology
5.10.1 Tiba Biotechnology Corporation Information
5.10.2 Tiba Biotechnology Description, Business Overview
5.10.3 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Products Offered
5.10.4 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2020-2025)
5.10.5 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue by Product in 2024
5.10.6 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue by Application in 2024
5.10.7 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue by Geographic Area in 2024
5.10.8 Tiba Biotechnology Recent Developments
6 North America
6.1 North America mRNA Cancer Vaccines and Therapeutics Market Size YoY Growth 2020-2031
6.2 North America mRNA Cancer Vaccines and Therapeutics Market Facts & Figures by Country (2020-2031)
6.3 North America mRNA Cancer Vaccines and Therapeutics Revenue by Type (2020-2025)
6.4 North America mRNA Cancer Vaccines and Therapeutics Revenue by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Market Size YoY Growth 2020-2031
7.2 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Market Facts & Figures by Region (2020-2031)
7.3 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue by Type (2020-2025)
7.4 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue by Application (2020-2025)
8 Europe
8.1 Europe mRNA Cancer Vaccines and Therapeutics Market Size YoY Growth 2020-2031
8.2 Europe mRNA Cancer Vaccines and Therapeutics Market Facts & Figures by Country (2020-2031)
8.3 Europe mRNA Cancer Vaccines and Therapeutics Revenue by Type (2020-2025)
8.4 Europe mRNA Cancer Vaccines and Therapeutics Revenue by Application (2020-2025)
9 Latin America
9.1 Latin America mRNA Cancer Vaccines and Therapeutics Market Size YoY Growth 2020-2031
9.2 Latin America mRNA Cancer Vaccines and Therapeutics Market Facts & Figures by Country (2020-2031)
9.3 Latin America mRNA Cancer Vaccines and Therapeutics Revenue by Type (2020-2025)
9.4 Latin America mRNA Cancer Vaccines and Therapeutics Revenue by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America mRNA Cancer Vaccines and Therapeutics Market Size YoY Growth 2020-2031
10.2 Middle East and Africa mRNA Cancer Vaccines and Therapeutics Market Facts & Figures by Country (2020-2031)
10.3 Middle East and Africa mRNA Cancer Vaccines and Therapeutics Revenue by Type (2020-2025)
10.4 Middle East and Africa mRNA Cancer Vaccines and Therapeutics Revenue by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 mRNA Cancer Vaccines and Therapeutics Supply Chain Analysis
11.2 mRNA Cancer Vaccines and Therapeutics Key Raw Materials and Upstream Suppliers
11.3 mRNA Cancer Vaccines and Therapeutics Clients Analysis
11.4 mRNA Cancer Vaccines and Therapeutics Sales Channel and Sales Model Analysis
11.4.1 mRNA Cancer Vaccines and Therapeutics Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 mRNA Cancer Vaccines and Therapeutics Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 mRNA Cancer Vaccines and Therapeutics Distributors
12 mRNA Cancer Vaccines and Therapeutics Market Dynamics
12.1 mRNA Cancer Vaccines and Therapeutics Industry Trends
12.2 mRNA Cancer Vaccines and Therapeutics Market Drivers
12.3 mRNA Cancer Vaccines and Therapeutics Market Challenges
12.4 mRNA Cancer Vaccines and Therapeutics Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
1.1 mRNA Cancer Vaccines and Therapeutics Product Introduction
1.2 Market by Type
1.2.1 Global mRNA Cancer Vaccines and Therapeutics Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Adeno Carcinomas
1.2.3 Mucinous Carcinomas
1.2.4 Adenosquamous Carcinomas
1.3 Market by Application
1.3.1 Global mRNA Cancer Vaccines and Therapeutics Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Infectious Disease
1.3.3 Cancer
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global mRNA Cancer Vaccines and Therapeutics Market Size Estimates and Forecasts
2.2 mRNA Cancer Vaccines and Therapeutics Market Size by Region: 2024 Versus 2031
2.2.1 Global mRNA Cancer Vaccines and Therapeutics Revenue by Region: 2020-2025
2.2.2 Global mRNA Cancer Vaccines and Therapeutics Revenue Forecast by Region (2026-2031)
2.2.3 Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global mRNA Cancer Vaccines and Therapeutics Revenue by Type (2020-2031)
3.1.2 Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global mRNA Cancer Vaccines and Therapeutics Revenue by Application (2020-2031)
3.2.2 Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Adeno Carcinomas of mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application
3.3.2 Mucinous Carcinomas of mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application
3.3.3 Adenosquamous Carcinomas of mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application
4 Global mRNA Cancer Vaccines and Therapeutics by Company
4.1 Global mRNA Cancer Vaccines and Therapeutics Revenue by Company (2020-2025)
4.2 Global mRNA Cancer Vaccines and Therapeutics Revenue Share by Company (2020-2025)
4.3 Competitive Landscape
4.3.1 Key mRNA Cancer Vaccines and Therapeutics Companies around the World: Ranking by Revenue
4.3.2 Global mRNA Cancer Vaccines and Therapeutics Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.3.3 Global mRNA Cancer Vaccines and Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 Global mRNA Cancer Vaccines and Therapeutics Companies Headquarters & Product Type
4.4.1 Global mRNA Cancer Vaccines and Therapeutics Companies Headquarters
4.4.2 Date of International Companies Enter into mRNA Cancer Vaccines and Therapeutics Market
4.4.3 Global mRNA Cancer Vaccines and Therapeutics Companies Product & Service
4.4.4 Adeno Carcinomas Revenue Market Share of mRNA Cancer Vaccines and Therapeutics by Company
4.4.5 Mucinous Carcinomas Revenue Market Share of mRNA Cancer Vaccines and Therapeutics by Company
4.4.6 Adenosquamous Carcinomas Revenue Market Share of mRNA Cancer Vaccines and Therapeutics by Company
4.5 Global mRNA Cancer Vaccines and Therapeutics Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Moderna Therapeutics
5.1.1 Moderna Therapeutics Corporation Information
5.1.2 Moderna Therapeutics Description, Business Overview
5.1.3 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Products Offered
5.1.4 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2020-2025)
5.1.5 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue by Product in 2024
5.1.6 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue by Application in 2024
5.1.7 Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue by Geographic Area in 2024
5.1.8 Moderna Therapeutics Recent Developments
5.2 CureVac
5.2.1 CureVac Corporation Information
5.2.2 CureVac Description, Business Overview
5.2.3 CureVac mRNA Cancer Vaccines and Therapeutics Products Offered
5.2.4 CureVac mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2020-2025)
5.2.5 CureVac mRNA Cancer Vaccines and Therapeutics Revenue by Product in 2024
5.2.6 CureVac mRNA Cancer Vaccines and Therapeutics Revenue by Application in 2024
5.2.7 CureVac mRNA Cancer Vaccines and Therapeutics Revenue by Geographic Area in 2024
5.2.8 CureVac Recent Developments
5.3 Translate Bio
5.3.1 Translate Bio Corporation Information
5.3.2 Translate Bio Description, Business Overview
5.3.3 Translate Bio mRNA Cancer Vaccines and Therapeutics Products Offered
5.3.4 Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2020-2025)
5.3.5 Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue by Product in 2024
5.3.6 Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue by Application in 2024
5.3.7 Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue by Geographic Area in 2024
5.3.8 Translate Bio Recent Developments
5.4 BioNTech
5.4.1 BioNTech Corporation Information
5.4.2 BioNTech Description, Business Overview
5.4.3 BioNTech mRNA Cancer Vaccines and Therapeutics Products Offered
5.4.4 BioNTech mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2020-2025)
5.4.5 BioNTech mRNA Cancer Vaccines and Therapeutics Revenue by Product in 2024
5.4.6 BioNTech mRNA Cancer Vaccines and Therapeutics Revenue by Application in 2024
5.4.7 BioNTech mRNA Cancer Vaccines and Therapeutics Revenue by Geographic Area in 2024
5.4.8 BioNTech Recent Developments
5.5 Sangamo Therapeutics
5.5.1 Sangamo Therapeutics Corporation Information
5.5.2 Sangamo Therapeutics Description, Business Overview
5.5.3 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Products Offered
5.5.4 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2020-2025)
5.5.5 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue by Product in 2024
5.5.6 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue by Application in 2024
5.5.7 Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue by Geographic Area in 2024
5.5.8 Sangamo Therapeutics Recent Developments
5.6 Argos Therapeutics
5.6.1 Argos Therapeutics Corporation Information
5.6.2 Argos Therapeutics Description, Business Overview
5.6.3 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Products Offered
5.6.4 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2020-2025)
5.6.5 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue by Product in 2024
5.6.6 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue by Application in 2024
5.6.7 Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue by Geographic Area in 2024
5.6.8 Argos Therapeutics Recent Developments
5.7 In-Cell-Art
5.7.1 In-Cell-Art Corporation Information
5.7.2 In-Cell-Art Description, Business Overview
5.7.3 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Products Offered
5.7.4 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2020-2025)
5.7.5 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue by Product in 2024
5.7.6 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue by Application in 2024
5.7.7 In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue by Geographic Area in 2024
5.7.8 In-Cell-Art Recent Developments
5.8 eTheRNA
5.8.1 eTheRNA Corporation Information
5.8.2 eTheRNA Description, Business Overview
5.8.3 eTheRNA mRNA Cancer Vaccines and Therapeutics Products Offered
5.8.4 eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2020-2025)
5.8.5 eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue by Product in 2024
5.8.6 eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue by Application in 2024
5.8.7 eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue by Geographic Area in 2024
5.8.8 eTheRNA Recent Developments
5.9 Ethris
5.9.1 Ethris Corporation Information
5.9.2 Ethris Description, Business Overview
5.9.3 Ethris mRNA Cancer Vaccines and Therapeutics Products Offered
5.9.4 Ethris mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2020-2025)
5.9.5 Ethris mRNA Cancer Vaccines and Therapeutics Revenue by Product in 2024
5.9.6 Ethris mRNA Cancer Vaccines and Therapeutics Revenue by Application in 2024
5.9.7 Ethris mRNA Cancer Vaccines and Therapeutics Revenue by Geographic Area in 2024
5.9.8 Ethris Recent Developments
5.10 Tiba Biotechnology
5.10.1 Tiba Biotechnology Corporation Information
5.10.2 Tiba Biotechnology Description, Business Overview
5.10.3 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Products Offered
5.10.4 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue and Gross Margin (2020-2025)
5.10.5 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue by Product in 2024
5.10.6 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue by Application in 2024
5.10.7 Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue by Geographic Area in 2024
5.10.8 Tiba Biotechnology Recent Developments
6 North America
6.1 North America mRNA Cancer Vaccines and Therapeutics Market Size YoY Growth 2020-2031
6.2 North America mRNA Cancer Vaccines and Therapeutics Market Facts & Figures by Country (2020-2031)
6.3 North America mRNA Cancer Vaccines and Therapeutics Revenue by Type (2020-2025)
6.4 North America mRNA Cancer Vaccines and Therapeutics Revenue by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Market Size YoY Growth 2020-2031
7.2 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Market Facts & Figures by Region (2020-2031)
7.3 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue by Type (2020-2025)
7.4 Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue by Application (2020-2025)
8 Europe
8.1 Europe mRNA Cancer Vaccines and Therapeutics Market Size YoY Growth 2020-2031
8.2 Europe mRNA Cancer Vaccines and Therapeutics Market Facts & Figures by Country (2020-2031)
8.3 Europe mRNA Cancer Vaccines and Therapeutics Revenue by Type (2020-2025)
8.4 Europe mRNA Cancer Vaccines and Therapeutics Revenue by Application (2020-2025)
9 Latin America
9.1 Latin America mRNA Cancer Vaccines and Therapeutics Market Size YoY Growth 2020-2031
9.2 Latin America mRNA Cancer Vaccines and Therapeutics Market Facts & Figures by Country (2020-2031)
9.3 Latin America mRNA Cancer Vaccines and Therapeutics Revenue by Type (2020-2025)
9.4 Latin America mRNA Cancer Vaccines and Therapeutics Revenue by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America mRNA Cancer Vaccines and Therapeutics Market Size YoY Growth 2020-2031
10.2 Middle East and Africa mRNA Cancer Vaccines and Therapeutics Market Facts & Figures by Country (2020-2031)
10.3 Middle East and Africa mRNA Cancer Vaccines and Therapeutics Revenue by Type (2020-2025)
10.4 Middle East and Africa mRNA Cancer Vaccines and Therapeutics Revenue by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 mRNA Cancer Vaccines and Therapeutics Supply Chain Analysis
11.2 mRNA Cancer Vaccines and Therapeutics Key Raw Materials and Upstream Suppliers
11.3 mRNA Cancer Vaccines and Therapeutics Clients Analysis
11.4 mRNA Cancer Vaccines and Therapeutics Sales Channel and Sales Model Analysis
11.4.1 mRNA Cancer Vaccines and Therapeutics Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 mRNA Cancer Vaccines and Therapeutics Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 mRNA Cancer Vaccines and Therapeutics Distributors
12 mRNA Cancer Vaccines and Therapeutics Market Dynamics
12.1 mRNA Cancer Vaccines and Therapeutics Industry Trends
12.2 mRNA Cancer Vaccines and Therapeutics Market Drivers
12.3 mRNA Cancer Vaccines and Therapeutics Market Challenges
12.4 mRNA Cancer Vaccines and Therapeutics Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
List of Tables
Table 1. Global mRNA Cancer Vaccines and Therapeutics Market Size Growth Rate (CAGR) by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global mRNA Cancer Vaccines and Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global mRNA Cancer Vaccines and Therapeutics Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global mRNA Cancer Vaccines and Therapeutics Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global mRNA Cancer Vaccines and Therapeutics Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 6. Global mRNA Cancer Vaccines and Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 7. Global mRNA Cancer Vaccines and Therapeutics Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 8. Global mRNA Cancer Vaccines and Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 9. Global mRNA Cancer Vaccines and Therapeutics Revenue Forecast by Application (2026-2031) & (US$ Million)
Table 10. mRNA Cancer Vaccines and Therapeutics Revenue by Company (2020-2025) & (US$ Million)
Table 11. mRNA Cancer Vaccines and Therapeutics Revenue Share by Company (2020-2025)
Table 12. Ranking of Global Top mRNA Cancer Vaccines and Therapeutics Players by Revenue (US$ Million) in 2024
Table 13. Global mRNA Cancer Vaccines and Therapeutics Companies Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 14. Global mRNA Cancer Vaccines and Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in mRNA Cancer Vaccines and Therapeutics as of 2024)
Table 15. Global mRNA Cancer Vaccines and Therapeutics Companies Headquarters
Table 16. Date of International Companies Enter into mRNA Cancer Vaccines and Therapeutics Market
Table 17. Global mRNA Cancer Vaccines and Therapeutics Companies Product & Service
Table 18. Global mRNA Cancer Vaccines and Therapeutics Mergers & Acquisitions, Expansion Plans
Table 19. Moderna Therapeutics Corporation Information
Table 20. Moderna Therapeutics Description and Business Overview
Table 21. Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Product
Table 22. Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 23. Moderna Therapeutics Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Product in 2024
Table 24. Moderna Therapeutics Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Application in 2024
Table 25. Moderna Therapeutics Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Geographic Area in 2024
Table 26. Moderna Therapeutics Recent Developments
Table 27. CureVac Corporation Information
Table 28. CureVac Description and Business Overview
Table 29. CureVac mRNA Cancer Vaccines and Therapeutics Product
Table 30. CureVac mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 31. CureVac Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Product in 2024
Table 32. CureVac Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Application in 2024
Table 33. CureVac Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Geographic Area in 2024
Table 34. CureVac Recent Developments
Table 35. Translate Bio Corporation Information
Table 36. Translate Bio Description and Business Overview
Table 37. Translate Bio mRNA Cancer Vaccines and Therapeutics Product
Table 38. Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 39. Translate Bio Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Product in 2024
Table 40. Translate Bio Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Application in 2024
Table 41. Translate Bio Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Geographic Area in 2024
Table 42. Translate Bio Recent Developments
Table 43. BioNTech Corporation Information
Table 44. BioNTech Description and Business Overview
Table 45. BioNTech mRNA Cancer Vaccines and Therapeutics Product
Table 46. BioNTech mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. BioNTech Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Product in 2024
Table 48. BioNTech Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Application in 2024
Table 49. BioNTech Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Geographic Area in 2024
Table 50. BioNTech Recent Developments
Table 51. Sangamo Therapeutics Corporation Information
Table 52. Sangamo Therapeutics Description and Business Overview
Table 53. Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Product
Table 54. Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 55. Sangamo Therapeutics Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Product in 2024
Table 56. Sangamo Therapeutics Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Application in 2024
Table 57. Sangamo Therapeutics Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Geographic Area in 2024
Table 58. Sangamo Therapeutics Recent Developments
Table 59. Argos Therapeutics Corporation Information
Table 60. Argos Therapeutics Description and Business Overview
Table 61. Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Product
Table 62. Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 63. Argos Therapeutics Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Product in 2024
Table 64. Argos Therapeutics Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Application in 2024
Table 65. Argos Therapeutics Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Geographic Area in 2024
Table 66. Argos Therapeutics Recent Developments
Table 67. In-Cell-Art Corporation Information
Table 68. In-Cell-Art Description and Business Overview
Table 69. In-Cell-Art mRNA Cancer Vaccines and Therapeutics Product
Table 70. In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 71. In-Cell-Art Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Product in 2024
Table 72. In-Cell-Art Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Application in 2024
Table 73. In-Cell-Art Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Geographic Area in 2024
Table 74. In-Cell-Art Recent Developments
Table 75. eTheRNA Corporation Information
Table 76. eTheRNA Description and Business Overview
Table 77. eTheRNA mRNA Cancer Vaccines and Therapeutics Product
Table 78. eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 79. eTheRNA Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Product in 2024
Table 80. eTheRNA Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Application in 2024
Table 81. eTheRNA Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Geographic Area in 2024
Table 82. eTheRNA Recent Developments
Table 83. Ethris Corporation Information
Table 84. Ethris Description and Business Overview
Table 85. Ethris mRNA Cancer Vaccines and Therapeutics Product
Table 86. Ethris mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 87. Ethris Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Product in 2024
Table 88. Ethris Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Application in 2024
Table 89. Ethris Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Geographic Area in 2024
Table 90. Ethris Recent Developments
Table 91. Tiba Biotechnology Corporation Information
Table 92. Tiba Biotechnology Description and Business Overview
Table 93. Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Product
Table 94. Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 95. Tiba Biotechnology Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Product in 2024
Table 96. Tiba Biotechnology Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Application in 2024
Table 97. Tiba Biotechnology Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Geographic Area in 2024
Table 98. Tiba Biotechnology Recent Developments
Table 99. North America mRNA Cancer Vaccines and Therapeutics Revenue by Country (2020-2025) & (US$ Million)
Table 100. North America mRNA Cancer Vaccines and Therapeutics Revenue by Country (2026-2031) & (US$ Million)
Table 101. North America mRNA Cancer Vaccines and Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 102. North America mRNA Cancer Vaccines and Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 103. Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue by Region (2020-2025) & (US$ Million)
Table 104. Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue by Region (2026-2031) & (US$ Million)
Table 105. Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 106. Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 107. Europe mRNA Cancer Vaccines and Therapeutics Revenue by Country (2020-2025) & (US$ Million)
Table 108. Europe mRNA Cancer Vaccines and Therapeutics Revenue by Country (2026-2031) & (US$ Million)
Table 109. Europe mRNA Cancer Vaccines and Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 110. Europe mRNA Cancer Vaccines and Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 111. Latin America mRNA Cancer Vaccines and Therapeutics Revenue by Country (2020-2025) & (US$ Million)
Table 112. Latin America mRNA Cancer Vaccines and Therapeutics Revenue by Country (2026-2031) & (US$ Million)
Table 113. Latin America mRNA Cancer Vaccines and Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 114. Latin America mRNA Cancer Vaccines and Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 115. Middle East and Africa mRNA Cancer Vaccines and Therapeutics Revenue by Country (2020-2025) & (US$ Million)
Table 116. Middle East and Africa mRNA Cancer Vaccines and Therapeutics Revenue by Country (2026-2031) & (US$ Million)
Table 117. Middle East and Africa mRNA Cancer Vaccines and Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 118. Middle East and Africa mRNA Cancer Vaccines and Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 119. mRNA Cancer Vaccines and Therapeutics Key Raw Materials, Industry Status and Trend
Table 120. mRNA Cancer Vaccines and Therapeutics Key Raw Materials and Upstream Suppliers
Table 121. mRNA Cancer Vaccines and Therapeutics Clients Status and Trend
Table 122. mRNA Cancer Vaccines and Therapeutics Typical Clients
Table 123. mRNA Cancer Vaccines and Therapeutics Distributors
Table 124. mRNA Cancer Vaccines and Therapeutics Market Trends
Table 125. mRNA Cancer Vaccines and Therapeutics Market Drivers
Table 126. mRNA Cancer Vaccines and Therapeutics Market Challenges
Table 127. mRNA Cancer Vaccines and Therapeutics Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. mRNA Cancer Vaccines and Therapeutics Product Picture
Figure 2. Global mRNA Cancer Vaccines and Therapeutics Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Type in 2024 & 2031
Figure 4. Adeno Carcinomas Product Picture
Figure 5. Mucinous Carcinomas Product Picture
Figure 6. Adenosquamous Carcinomas Product Picture
Figure 7. Global mRNA Cancer Vaccines and Therapeutics Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 8. Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application in 2024 & 2031
Figure 9. Infectious Disease
Figure 10. Cancer
Figure 11. Others
Figure 12. mRNA Cancer Vaccines and Therapeutics Report Years Considered
Figure 13. Global mRNA Cancer Vaccines and Therapeutics Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global mRNA Cancer Vaccines and Therapeutics Market Size (2020-2031) & (US$ Million)
Figure 15. Global mRNA Cancer Vaccines and Therapeutics Market Size Market Share by Region: 2024 Versus 2031
Figure 16. Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Region (2020-2031)
Figure 17. Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share Forecast by Type (2020-2031)
Figure 18. Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share Forecast by Application (2020-2031)
Figure 19. Adeno Carcinomas of mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application, 2024 VS 2031
Figure 20. Mucinous Carcinomas of mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application, 2024 VS 2031
Figure 21. Adenosquamous Carcinomas of mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application, 2024 VS 2031
Figure 22. mRNA Cancer Vaccines and Therapeutics Revenue Share by Company (2024)
Figure 23. mRNA Cancer Vaccines and Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 24. Adeno Carcinomas Revenue Proportion by Company in 2024
Figure 25. Mucinous Carcinomas Revenue Proportion by Company in 2024
Figure 26. Adenosquamous Carcinomas Revenue Proportion by Company in 2024
Figure 27. North America mRNA Cancer Vaccines and Therapeutics Revenue 2020-2031 (US$ Million)
Figure 28. North America mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Type (2020-2025)
Figure 29. North America mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application (2020-2025)
Figure 30. Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue 2020-2031 (US$ Million)
Figure 31. Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Region (2020-2031)
Figure 32. Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Type (2020-2025)
Figure 33. Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application (2020-2025)
Figure 34. Europe mRNA Cancer Vaccines and Therapeutics Revenue Growth Rate 2020-2031 (US$ Million)
Figure 35. Europe mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Country (2020-2031)
Figure 36. Europe mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Type (2020-2025)
Figure 37. Europe mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application (2020-2025)
Figure 38. Latin America mRNA Cancer Vaccines and Therapeutics Revenue Growth Rate 2020-2031 (US$ Million)
Figure 39. Latin America mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Country (2020-2031)
Figure 40. Latin America mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Type (2020-2025)
Figure 41. Latin America mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application (2020-2025)
Figure 42. Middle East and Africa mRNA Cancer Vaccines and Therapeutics Revenue Growth Rate 2020-2031 (US$ Million)
Figure 43. Middle East and Africa mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Country (2020-2031)
Figure 44. Middle East and Africa mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Type (2020-2025)
Figure 45. Middle East and Africa mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application (2020-2025)
Figure 46. mRNA Cancer Vaccines and Therapeutics Supply Chain (Upstream and Downstream Market)
Figure 47. Global Production Market Share of mRNA Cancer Vaccines and Therapeutics Raw Materials by Region in 2024
Figure 48. mRNA Cancer Vaccines and Therapeutics Distribution Channels
Figure 49. Global mRNA Cancer Vaccines and Therapeutics Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 50. Global mRNA Cancer Vaccines and Therapeutics Percentage 2020-2031: Online Sales VS Offline Sales
Figure 51. Bottom-up and Top-down Approaches for This Report
Figure 52. Data Triangulation
Figure 53. Key Executives Interviewed
Table 1. Global mRNA Cancer Vaccines and Therapeutics Market Size Growth Rate (CAGR) by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global mRNA Cancer Vaccines and Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global mRNA Cancer Vaccines and Therapeutics Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global mRNA Cancer Vaccines and Therapeutics Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global mRNA Cancer Vaccines and Therapeutics Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 6. Global mRNA Cancer Vaccines and Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 7. Global mRNA Cancer Vaccines and Therapeutics Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 8. Global mRNA Cancer Vaccines and Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 9. Global mRNA Cancer Vaccines and Therapeutics Revenue Forecast by Application (2026-2031) & (US$ Million)
Table 10. mRNA Cancer Vaccines and Therapeutics Revenue by Company (2020-2025) & (US$ Million)
Table 11. mRNA Cancer Vaccines and Therapeutics Revenue Share by Company (2020-2025)
Table 12. Ranking of Global Top mRNA Cancer Vaccines and Therapeutics Players by Revenue (US$ Million) in 2024
Table 13. Global mRNA Cancer Vaccines and Therapeutics Companies Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 14. Global mRNA Cancer Vaccines and Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in mRNA Cancer Vaccines and Therapeutics as of 2024)
Table 15. Global mRNA Cancer Vaccines and Therapeutics Companies Headquarters
Table 16. Date of International Companies Enter into mRNA Cancer Vaccines and Therapeutics Market
Table 17. Global mRNA Cancer Vaccines and Therapeutics Companies Product & Service
Table 18. Global mRNA Cancer Vaccines and Therapeutics Mergers & Acquisitions, Expansion Plans
Table 19. Moderna Therapeutics Corporation Information
Table 20. Moderna Therapeutics Description and Business Overview
Table 21. Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Product
Table 22. Moderna Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 23. Moderna Therapeutics Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Product in 2024
Table 24. Moderna Therapeutics Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Application in 2024
Table 25. Moderna Therapeutics Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Geographic Area in 2024
Table 26. Moderna Therapeutics Recent Developments
Table 27. CureVac Corporation Information
Table 28. CureVac Description and Business Overview
Table 29. CureVac mRNA Cancer Vaccines and Therapeutics Product
Table 30. CureVac mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 31. CureVac Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Product in 2024
Table 32. CureVac Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Application in 2024
Table 33. CureVac Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Geographic Area in 2024
Table 34. CureVac Recent Developments
Table 35. Translate Bio Corporation Information
Table 36. Translate Bio Description and Business Overview
Table 37. Translate Bio mRNA Cancer Vaccines and Therapeutics Product
Table 38. Translate Bio mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 39. Translate Bio Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Product in 2024
Table 40. Translate Bio Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Application in 2024
Table 41. Translate Bio Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Geographic Area in 2024
Table 42. Translate Bio Recent Developments
Table 43. BioNTech Corporation Information
Table 44. BioNTech Description and Business Overview
Table 45. BioNTech mRNA Cancer Vaccines and Therapeutics Product
Table 46. BioNTech mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. BioNTech Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Product in 2024
Table 48. BioNTech Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Application in 2024
Table 49. BioNTech Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Geographic Area in 2024
Table 50. BioNTech Recent Developments
Table 51. Sangamo Therapeutics Corporation Information
Table 52. Sangamo Therapeutics Description and Business Overview
Table 53. Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Product
Table 54. Sangamo Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 55. Sangamo Therapeutics Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Product in 2024
Table 56. Sangamo Therapeutics Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Application in 2024
Table 57. Sangamo Therapeutics Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Geographic Area in 2024
Table 58. Sangamo Therapeutics Recent Developments
Table 59. Argos Therapeutics Corporation Information
Table 60. Argos Therapeutics Description and Business Overview
Table 61. Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Product
Table 62. Argos Therapeutics mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 63. Argos Therapeutics Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Product in 2024
Table 64. Argos Therapeutics Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Application in 2024
Table 65. Argos Therapeutics Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Geographic Area in 2024
Table 66. Argos Therapeutics Recent Developments
Table 67. In-Cell-Art Corporation Information
Table 68. In-Cell-Art Description and Business Overview
Table 69. In-Cell-Art mRNA Cancer Vaccines and Therapeutics Product
Table 70. In-Cell-Art mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 71. In-Cell-Art Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Product in 2024
Table 72. In-Cell-Art Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Application in 2024
Table 73. In-Cell-Art Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Geographic Area in 2024
Table 74. In-Cell-Art Recent Developments
Table 75. eTheRNA Corporation Information
Table 76. eTheRNA Description and Business Overview
Table 77. eTheRNA mRNA Cancer Vaccines and Therapeutics Product
Table 78. eTheRNA mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 79. eTheRNA Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Product in 2024
Table 80. eTheRNA Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Application in 2024
Table 81. eTheRNA Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Geographic Area in 2024
Table 82. eTheRNA Recent Developments
Table 83. Ethris Corporation Information
Table 84. Ethris Description and Business Overview
Table 85. Ethris mRNA Cancer Vaccines and Therapeutics Product
Table 86. Ethris mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 87. Ethris Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Product in 2024
Table 88. Ethris Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Application in 2024
Table 89. Ethris Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Geographic Area in 2024
Table 90. Ethris Recent Developments
Table 91. Tiba Biotechnology Corporation Information
Table 92. Tiba Biotechnology Description and Business Overview
Table 93. Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Product
Table 94. Tiba Biotechnology mRNA Cancer Vaccines and Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 95. Tiba Biotechnology Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Product in 2024
Table 96. Tiba Biotechnology Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Application in 2024
Table 97. Tiba Biotechnology Revenue Proportion of mRNA Cancer Vaccines and Therapeutics by Geographic Area in 2024
Table 98. Tiba Biotechnology Recent Developments
Table 99. North America mRNA Cancer Vaccines and Therapeutics Revenue by Country (2020-2025) & (US$ Million)
Table 100. North America mRNA Cancer Vaccines and Therapeutics Revenue by Country (2026-2031) & (US$ Million)
Table 101. North America mRNA Cancer Vaccines and Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 102. North America mRNA Cancer Vaccines and Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 103. Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue by Region (2020-2025) & (US$ Million)
Table 104. Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue by Region (2026-2031) & (US$ Million)
Table 105. Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 106. Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 107. Europe mRNA Cancer Vaccines and Therapeutics Revenue by Country (2020-2025) & (US$ Million)
Table 108. Europe mRNA Cancer Vaccines and Therapeutics Revenue by Country (2026-2031) & (US$ Million)
Table 109. Europe mRNA Cancer Vaccines and Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 110. Europe mRNA Cancer Vaccines and Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 111. Latin America mRNA Cancer Vaccines and Therapeutics Revenue by Country (2020-2025) & (US$ Million)
Table 112. Latin America mRNA Cancer Vaccines and Therapeutics Revenue by Country (2026-2031) & (US$ Million)
Table 113. Latin America mRNA Cancer Vaccines and Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 114. Latin America mRNA Cancer Vaccines and Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 115. Middle East and Africa mRNA Cancer Vaccines and Therapeutics Revenue by Country (2020-2025) & (US$ Million)
Table 116. Middle East and Africa mRNA Cancer Vaccines and Therapeutics Revenue by Country (2026-2031) & (US$ Million)
Table 117. Middle East and Africa mRNA Cancer Vaccines and Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 118. Middle East and Africa mRNA Cancer Vaccines and Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 119. mRNA Cancer Vaccines and Therapeutics Key Raw Materials, Industry Status and Trend
Table 120. mRNA Cancer Vaccines and Therapeutics Key Raw Materials and Upstream Suppliers
Table 121. mRNA Cancer Vaccines and Therapeutics Clients Status and Trend
Table 122. mRNA Cancer Vaccines and Therapeutics Typical Clients
Table 123. mRNA Cancer Vaccines and Therapeutics Distributors
Table 124. mRNA Cancer Vaccines and Therapeutics Market Trends
Table 125. mRNA Cancer Vaccines and Therapeutics Market Drivers
Table 126. mRNA Cancer Vaccines and Therapeutics Market Challenges
Table 127. mRNA Cancer Vaccines and Therapeutics Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. mRNA Cancer Vaccines and Therapeutics Product Picture
Figure 2. Global mRNA Cancer Vaccines and Therapeutics Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Type in 2024 & 2031
Figure 4. Adeno Carcinomas Product Picture
Figure 5. Mucinous Carcinomas Product Picture
Figure 6. Adenosquamous Carcinomas Product Picture
Figure 7. Global mRNA Cancer Vaccines and Therapeutics Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 8. Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application in 2024 & 2031
Figure 9. Infectious Disease
Figure 10. Cancer
Figure 11. Others
Figure 12. mRNA Cancer Vaccines and Therapeutics Report Years Considered
Figure 13. Global mRNA Cancer Vaccines and Therapeutics Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global mRNA Cancer Vaccines and Therapeutics Market Size (2020-2031) & (US$ Million)
Figure 15. Global mRNA Cancer Vaccines and Therapeutics Market Size Market Share by Region: 2024 Versus 2031
Figure 16. Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Region (2020-2031)
Figure 17. Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share Forecast by Type (2020-2031)
Figure 18. Global mRNA Cancer Vaccines and Therapeutics Revenue Market Share Forecast by Application (2020-2031)
Figure 19. Adeno Carcinomas of mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application, 2024 VS 2031
Figure 20. Mucinous Carcinomas of mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application, 2024 VS 2031
Figure 21. Adenosquamous Carcinomas of mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application, 2024 VS 2031
Figure 22. mRNA Cancer Vaccines and Therapeutics Revenue Share by Company (2024)
Figure 23. mRNA Cancer Vaccines and Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 24. Adeno Carcinomas Revenue Proportion by Company in 2024
Figure 25. Mucinous Carcinomas Revenue Proportion by Company in 2024
Figure 26. Adenosquamous Carcinomas Revenue Proportion by Company in 2024
Figure 27. North America mRNA Cancer Vaccines and Therapeutics Revenue 2020-2031 (US$ Million)
Figure 28. North America mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Type (2020-2025)
Figure 29. North America mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application (2020-2025)
Figure 30. Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue 2020-2031 (US$ Million)
Figure 31. Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Region (2020-2031)
Figure 32. Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Type (2020-2025)
Figure 33. Asia-Pacific mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application (2020-2025)
Figure 34. Europe mRNA Cancer Vaccines and Therapeutics Revenue Growth Rate 2020-2031 (US$ Million)
Figure 35. Europe mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Country (2020-2031)
Figure 36. Europe mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Type (2020-2025)
Figure 37. Europe mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application (2020-2025)
Figure 38. Latin America mRNA Cancer Vaccines and Therapeutics Revenue Growth Rate 2020-2031 (US$ Million)
Figure 39. Latin America mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Country (2020-2031)
Figure 40. Latin America mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Type (2020-2025)
Figure 41. Latin America mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application (2020-2025)
Figure 42. Middle East and Africa mRNA Cancer Vaccines and Therapeutics Revenue Growth Rate 2020-2031 (US$ Million)
Figure 43. Middle East and Africa mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Country (2020-2031)
Figure 44. Middle East and Africa mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Type (2020-2025)
Figure 45. Middle East and Africa mRNA Cancer Vaccines and Therapeutics Revenue Market Share by Application (2020-2025)
Figure 46. mRNA Cancer Vaccines and Therapeutics Supply Chain (Upstream and Downstream Market)
Figure 47. Global Production Market Share of mRNA Cancer Vaccines and Therapeutics Raw Materials by Region in 2024
Figure 48. mRNA Cancer Vaccines and Therapeutics Distribution Channels
Figure 49. Global mRNA Cancer Vaccines and Therapeutics Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 50. Global mRNA Cancer Vaccines and Therapeutics Percentage 2020-2031: Online Sales VS Offline Sales
Figure 51. Bottom-up and Top-down Approaches for This Report
Figure 52. Data Triangulation
Figure 53. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Natural Cocoa Extracts Market Research Report 2026
May 01, 26
Global Semiconductor Switched Mode Power Supply Market Research Report 2026
May 01, 26
Global Silicone Coated Spandrel Glass Market Research Report 2026
May 01, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232